Project Grant R21AI193195
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$440K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $667,013.00 to The University of Texas Southwestern Medical Center (UT Southwestern) to develop and validate deep learning models for accurately identifying antibody-antigen interactions and binding epitopes from massive sequencing data. The project aims to leverage machine learning and emerging...
This federal Project Grant award of $586,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at the University of Massachusetts Medical School (UMass Medical) to investigate the generation and regulation of TFH13 cells that drive pathogenic IgE in allergic conditions. The overarching goal is to elucidate the pathways leading to TFH13 cell differentiation, which play a critical...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $936,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The 5-year grant, which commenced on August 12, 2024, will support research to elucidate the regulation and function of tissue-resident eosinophils in allergic microenvironments. The project aims to 1) target cell cycle machinery to manipulate eosinophil specialization, 2) delineate pre-...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $175,000 to the La Jolla Institute for Immunology to study the role of Alternaria fungal sensitization in asthma pathogenesis. The research aims to determine the association between Alternaria-specific T cells and protection against Alternaria sensitization, as well as identify Alternaria-specific T cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $320,863 to Aaiit LLC (Inflammation Immuno Therapy) to develop a bifunctional IgE antagonist and dissociator (ANDI) drug to treat severe allergic asthma. The ANDI drug aims to directly access and dissociate IgE bound to mast cell receptors, in contrast to the first-generation Xolair drug which only...
This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $151,444 to The Children's Hospital of Philadelphia (CHOP) to study the development of pediatric allergic diseases and create allergy prediction models using electronic health record (EHR) data. The overarching goal is to improve outcomes in pediatric allergy by understanding the heterogeneous "allergic...
This Project Grant award, valued at $185,866.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of airway epithelial syndecan-1 (SDC1) cleavage by leukocyte-derived heparanases in driving inflammation, barrier dysfunction, and steroid resistance in a preclinical model of severe, mixed-granulocytic allergic asthma. The research will evaluate the...
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $2,606,605.00 in funding to National Jewish Health over a period of approximately 5 years starting on September 6, 2024. The award supports research to decipher the role of early-life skin dysfunction in the development of the "allergic march" - the sequential progression from atopic...
This Project Grant award, valued at $162,000.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research at Indiana University Indianapolis to investigate the role of TGF-beta signaling in regulating T follicular helper (Tfh) cell differentiation and mast cell function, with the goal of better understanding the pathogenesis of allergic diseases. Key objectives include...